Atossa Therapeutics (NASDAQ:ATOS) Announces Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Atossa Therapeutics (NASDAQ:ATOS) released its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01, Zacks reports.

Atossa Therapeutics Trading Down 1.9 %

ATOS traded down $0.01 during trading hours on Tuesday, hitting $0.73. 100,420 shares of the company’s stock were exchanged, compared to its average volume of 1,017,699. The firm has a market cap of $92.34 million, a P/E ratio of -3.40 and a beta of 1.20. Atossa Therapeutics has a 12-month low of $0.66 and a 12-month high of $2.31. The firm has a 50 day moving average of $0.80 and a 200 day moving average of $1.12.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ATOS shares. Ascendiant Capital Markets increased their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 9th. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research note on Wednesday, March 12th.

Institutional Investors Weigh In On Atossa Therapeutics

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE boosted its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 111,475 shares of the company’s stock after buying an additional 37,809 shares during the quarter. Bank of America Corp DE owned approximately 0.09% of Atossa Therapeutics worth $105,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.